Trial Profile
A Randomized Double-blinded Placebo Controlled Single Center Phase I Study of Escalating Single Intravenous Doses of NI-0501 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Emapalumab (Primary)
- Indications COVID 2019 infections; Haemophagocytic lymphohistiocytosis; Transplant rejection
- Focus Adverse reactions; First in man
- Sponsors Light Chain Bioscience; Swedish Orphan Biovitrum
- 28 Feb 2014 New trial record